| | Identification | Back Directory |  | [Name] 
 11-Dideuterolinoleic acid
 |  | [CAS] 
 1051366-32-5
 |  | [Synonyms] 
 POL-6326)
 Balixafortide TFA salt
 Balixafortide
(POL6326
 11-Dideuterolinoleic acid
 Cyclo[L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl], cyclic (2→9)-disulfide
 |  | [Molecular Formula] 
 C84H118N24O21S2
 |  | [MDL Number] 
 MFCD34187225
 |  | [MOL File] 
 1051366-32-5.mol
 |  | [Molecular Weight] 
 1864.11
 | 
 | Chemical Properties | Back Directory |  | [density ] 
 1.58±0.1 g/cm3(Predicted)
 |  | [storage temp. ] 
 Store at -20°C
 |  | [solubility ] 
 DMSO:100.0(Max Conc. mg/mL);45.33(Max Conc. mM)
 Water:100.0(Max Conc. mg/mL);45.33(Max Conc. mM)
 |  | [pka] 
 9.89±0.15(Predicted)
 |  | [Water Solubility ] 
 Water: 100 mg/mL (53.64 mM);
 |  | [Sequence] 
 H-Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His-OH(Disulfide bridges Cys-Cys)
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2].
 |  | [in vivo] 
 
 Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability[1]. |  | [IC 50] 
 CXCR4: <10 nM (IC50)
 |  | [References] 
 [1] Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.
 [2] Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2. DOI:10.1186/s12967-016-1107-2
 | 
 | 
                    
                        
                            | Company Name: | InvivoChem |  
                            | Tel: | 13549236410 |  
                            | Website: | https://www.invivochem.cn/ |  |